Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers for acute coronary disorder

A technology for acute heart disease, disease, applied in the application field of acute coronary syndrome, which can solve the problem of not providing time course information, etc.

Inactive Publication Date: 2011-06-01
OTAGO INNOVATION
View PDF49 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Does not provide time-course information on when ANP-SP or BNP-SP levels were detected

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers for acute coronary disorder
  • Biomarkers for acute coronary disorder
  • Biomarkers for acute coronary disorder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0316] method

[0317] The all-owner protocol was approved by the Upper South Regional Ethics Committee of the Ministry of Health, New Zealand, and was conducted in accordance with the Declaration of Helsinki.

[0318] Chemicals

[0319] Synthetic human ANP signal peptide ANP-SP(16-25) (SEQ ID NO: 12) and ANP-SP(1-10) (SEQ ID NO: 16) is a mild Fmoc solid-phase synthesis method 29 Synthesized by Mimotopes (Australia). All buffer reagents were purchased from BDH (UK) and / or Sigma (Mo, USA). ANP-SP(16-25) was synthesized with a C-terminus extended with a cysteine ​​for directional carrier coupling. ANP-SP(16-25) also has a C-terminal extension with a tyrosyl residue for tracer preparation on the same peptide.

[0320] human studies

[0321] For the healthy volunteer reference range study, blood samples were initially obtained from 8 healthy volunteers (5 women, 3 men, mean age 47 ± 8 years (range 31-65 years), BMI 25.1 ± 3.2 years after overnight fasting kg / m 2 ).

[...

Embodiment 2

[0343] Eight patients with clinically stable suspected ACS were intubated and blood samples obtained from multiple organ sites: femoral artery (FA), hepatic vein (HV), inferior vena cava (IVC ), coronary sinus veins (CS), and pulmonary arteries (PA). Blood was collected into frozen EDTA tubes, prepared from plasma by centrifugation and subjected to ANP-SP RIA on plasma. Image 6 It clearly shows that the highest site of ANP-SP concentration is in the CS, the venous emptying of the heart, especially the ventricle. This is strong evidence that the heart is the major site of ANP-SP secretion and is consistent with the known gene expression pattern of ANP, which is highest in the heart.

[0344] in conclusion

[0345] Circulating ANP-SP concentrations in clinically stable patients were of cardiac origin. Significant cardiac secretion is consistent with ANP-SP being a cardiac hormone.

[0346] discuss

[0347] This evidence demonstrates for the first time that within two hou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring ANP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder of transplant rejection. Also provided are antibodies useful in the methods of the invention.

Description

technical field [0001] The present invention relates to ANP signal peptide (ANP-SP) and its use in prognosis, diagnosis and monitoring of acute cardiac diseases, including acute coronary syndromes, resulting in the release of biomarkers (biomarkers) into the circulation in subjects . More specifically, the present invention relates to methods of predicting, diagnosing or monitoring acute cardiac disease in a subject by measuring ANP-SP levels in samples taken shortly after disease onset or clinical manifestation. Background technique [0002] Acute cardiac disease, including acute coronary syndrome (ACS), covers a broad spectrum of cardiac ischemic events: from unstable angina to acute myocardial infarction (AMI). Of these events, AMI appears to be the most severe and thus requires rapid and accurate diagnosis. Patients presenting with two or more of the described features (history of ischemic chest discomfort, developmental changes on serial electrocardiogram (ECG) traces...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/53G01N33/68C07K7/06
CPCC07K16/26
Inventor 克里斯托弗·约瑟夫·彭伯顿阿瑟·马克·理查兹迈克尔·加里·尼科尔斯蒂莫西·格兰特·扬德尔
Owner OTAGO INNOVATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com